Chronic Inducible Urticaria Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Celldex Therapeutics, Jasper Therapeutics

Chronic Inducible Urticaria Pipeline constitutes 4+ key companies continuously working towards developing 4+ Chronic Inducible Urticaria treatment therapies, analyzes DelveInsight.

Chronic Inducible Urticaria Overview:

Chronic Inducible Urticaria (CIndU) is a form of chronic urticaria triggered by specific physical or environmental factors, such as pressure, temperature changes, sunlight, or exercise. Unlike chronic spontaneous urticaria, which occurs without an apparent cause, CIndU results from identifiable stimuli, making it unpredictable and challenging to manage.

The condition arises from an overactive immune response, where mast cells release histamine and inflammatory mediators in reaction to triggers, leading to itching, redness, and swelling. Treatment typically involves antihistamines, leukotriene receptor antagonists, and, in severe cases, immunomodulatory therapies aimed at controlling symptoms.

Request for a detailed insights report on Chronic Inducible Urticaria pipeline insights @ https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Chronic Inducible Urticaria Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Inducible Urticaria Therapeutics Market.

Key Takeaways from the Chronic Inducible Urticaria Pipeline Report

DelveInsight's Chronic Inducible Urticaria pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Chronic Inducible Urticaria treatment.
Key Chronic Inducible Urticaria companies such as Celldex Therapeutics, Jasper Therapeutics, and others are evaluating new drugs for Chronic Inducible Urticaria to improve the treatment landscape.
Promising Chronic Inducible Urticaria pipeline therapies in various stages of development include Barzolvolimab, and others.

Recent breakthroughs in the Chronic Inducible Urticaria Pipeline Segment:

In December 2024, Jasper Therapeutics presented preliminary results from the Phase 1b/2a SPOTLIGHT study evaluating briquilimab, a monoclonal antibody targeting mast cells. Patients with CIndU showed rapid and significant responses, with 93% achieving partial or complete response within six weeks. The treatment was well-tolerated, with no serious adverse events reported. These findings suggest briquilimab's potential as a novel treatment option for CIndU.
Nemolizumab, an interleukin-31 receptor antagonist, received approval from the U.S. Food and Drug Administration (FDA) in August 2024 and from the European Union in February 2025. By inhibiting IL-31-induced responses, nemolizumab prevents the release of proinflammatory cytokines and chemokines. While its primary indications include conditions like atopic dermatitis, its mechanism may offer insights into potential applications for CIndU in the future.
In October 2024, Celldex Therapeutics announced positive results from their Phase 2 study of barzolvolimab, a humanized monoclonal antibody targeting the KIT receptor tyrosine kinase. The study met all primary and secondary endpoints with high statistical significance, demonstrating favorable safety and tolerability. These findings mark the first successful demonstration of clinical benefit in a large, randomized, placebo-controlled study for CIndU, leading Celldex to plan Phase 3 development in 2025.

Chronic Inducible Urticaria Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Chronic Inducible Urticaria Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Inducible Urticaria treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Inducible Urticaria market.

Download our free sample page report on Chronic Inducible Urticaria pipeline insights @ https://www.delveinsight.com/sample-request/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Inducible Urticaria Emerging Drugs

Barzolvolimab: Celldex Therapeutics

Barzolvolimab is a humanized monoclonal antibody created by Celldex Therapeutics to target inflammatory and allergic conditions. It selectively binds to the receptor tyrosine kinase KIT with high specificity, effectively inhibiting its activity, which is essential for mast cell function and survival. Since mast cells are key players in inflammatory responses, including hypersensitivity and allergic reactions, this inhibition helps regulate these conditions. Barzolvolimab is currently undergoing Phase II clinical trials for the treatment of Chronic Inducible Urticaria.

Chronic Inducible Urticaria Companies

Several key companies are actively developing therapies for Chronic Inducible Urticaria. Among them, Celldex Therapeutics has a drug candidate in the most advanced stage, currently in Phase II clinical trials.

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Chronic Inducible Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Chronic Inducible Urticaria Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Chronic Inducible Urticaria Therapies and Key Companies: Chronic Inducible Urticaria Clinical Trials and advancements @ https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Inducible Urticaria Pipeline Therapeutic Assessment
• Chronic Inducible Urticaria Assessment by Product Type
• Chronic Inducible Urticaria By Stage
• Chronic Inducible Urticaria Assessment by Route of Administration
• Chronic Inducible Urticaria Assessment by Molecule Type

Download Chronic Inducible Urticaria Sample report to know in detail about the Chronic Inducible Urticaria treatment market @ Chronic Inducible Urticaria Therapeutic Assessment @ https://www.delveinsight.com/sample-request/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Chronic Inducible Urticaria Current Treatment Patterns
4. Chronic Inducible Urticaria - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chronic Inducible Urticaria Late-Stage Products (Phase-III)
7. Chronic Inducible Urticaria Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Inducible Urticaria Discontinued Products
13. Chronic Inducible Urticaria Product Profiles
14. Chronic Inducible Urticaria Key Companies
15. Chronic Inducible Urticaria Key Products
16. Dormant and Discontinued Products
17. Chronic Inducible Urticaria Unmet Needs
18. Chronic Inducible Urticaria Future Perspectives
19. Chronic Inducible Urticaria Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Chronic Inducible Urticaria Pipeline Reports Offerings: https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.